{"gene":"CASP8","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1996,"finding":"CASP8 (MACH/FLICE) was cloned as a novel protein that binds MORT1/FADD via its prodomain and contains an ICE/CED-3-like protease domain. Cellular expression of proteolytic MACH isoforms causes cell death downstream of Fas/APO-1 and p55-TNF receptor, establishing CASP8 as the most upstream enzymatic component in death receptor-induced apoptosis cascades.","method":"Yeast two-hybrid cloning, co-immunoprecipitation, cellular overexpression assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — original cloning paper with reciprocal binding and functional overexpression data, independently replicated by concurrent studies (Srinivasula et al., PMID:8962078)","pmids":["8681376"],"is_preprint":false},{"year":1996,"finding":"Recombinant Mch5/CASP8 (MACH/FLICE) is a mature two-subunit enzyme generated by autocleavage at Asp-227, Asp-233, Asp-391, and Asp-401. It directly processes and activates all known ICE/CED-3-like cysteine proteases (CPP32, Mch2, Mch3, Mch4, Mch6, ICE, TX, ICErelIII, ICH-1) and is potently inhibited by the cowpox serpin CrmA, placing it as the most upstream Fas-pathway protease.","method":"Bacterial recombinant expression, in vitro protease activity assays, N-terminal sequencing of cleavage products, CrmA inhibition assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted recombinant enzyme with in vitro substrate cleavage and inhibitor assays; replicated independently","pmids":["8962078"],"is_preprint":false},{"year":1997,"finding":"CASP8/FLICE is activated at the CD95 (Fas/APO-1) DISC by a two-step proteolytic mechanism: initial cleavage generates p43 and p12 fragments; subsequent cleavage of receptor-bound p43 releases the active-site-containing p18 fragment and prodomain p26. Activation requires association with the DISC (mediated by N-terminal DED binding to FADD) and is blocked by zVAD-fmk, zDEVD-fmk, and zIETD-fmk but not by CrmA or Ac-YVAD-CHO.","method":"Biochemical fractionation, immunoprecipitation of DISC components, western blot with cleavage-site antibodies, peptide inhibitor studies, mass spectrometry identification of DISC proteins","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods defining cleavage mechanism in the DISC; independently corroborated by Boldin et al. and Srinivasula et al.","pmids":["9184224"],"is_preprint":false},{"year":1997,"finding":"Recombinant FLICE/CASP8 directly activates downstream caspase zymogens in a cell-free system; CrmA attenuates this activation, consistent with CASP8 being the apical triggering protease in the CD95/TNFR-1-initiated caspase cascade.","method":"Cell-free system reconstitution, recombinant FLICE incubation with caspase zymogens, CrmA inhibition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with defined substrates and inhibitor; consistent with multiple independent studies","pmids":["9006941"],"is_preprint":false},{"year":1997,"finding":"Among eight described CASP8 isoforms, only caspase-8/a and caspase-8/b are detectably expressed at the protein level in cells of diverse origin. Both isoforms are recruited to the CD95 DISC and activated upon CD95 stimulation with similar kinetics.","method":"Monoclonal antibody panel generation, western blotting, immunoprecipitation of DISC, kinetics of activation assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antibody-based detection of specific isoforms at DISC, single lab, two orthogonal methods","pmids":["9341131"],"is_preprint":false},{"year":1998,"finding":"Genetic complementation of a caspase-8-deficient Jurkat cell line demonstrates that CASP8 is essential and apical in the Fas-induced apoptotic cascade. Loss of CASP8 completely abrogates Fas-induced apoptosis and blocks activation of multiple downstream caspases as well as stress kinases p38 and JNK. The deficient line is also severely impaired in TNF-α-induced cell death.","method":"Genetic screen, isolation of caspase-8-deficient cell line, complementation with wild-type CASP8, caspase activity assays, kinase activation assays","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic loss-of-function with complementation rescue, multiple pathway readouts, defines epistatic position of CASP8","pmids":["9740801"],"is_preprint":false},{"year":1999,"finding":"Anticancer drugs (daunorubicin, doxorubicin, etoposide, mitomycin C, cycloheximide) activate CASP8 in Jurkat cells independently of CD95 receptor/ligand interaction, as shown by equal drug-induced CASP8 activation in CD95-resistant cells and by failure of dominant-negative FADD (which blocks CD95 signaling) to prevent drug-induced CASP8 cleavage to its active p18 subunit.","method":"CD95-resistant cell lines, dominant-negative FADD overexpression, western blot for caspase-8 p18 fragment, caspase inhibitor studies","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (CD95-resistant cells, dominant-negative FADD, inhibitor studies) in one study; replicated by Engels et al. 2000","pmids":["10216102"],"is_preprint":false},{"year":2000,"finding":"In the mitochondrial (drug-induced) apoptosis pathway, CASP8 acts as an amplifying executioner caspase downstream of the mitochondria, not as the initiating protease. Anticancer drugs still process caspase-9, -3, and Bid in CASP8-deficient Jurkat cells; Bcl-xL overexpression or dominant-negative caspase-9 blocks drug-induced CASP8 processing; in caspase-3-lacking MCF7 cells, CASP8 is not activated by drugs unless caspase-3 is restored by transfection.","method":"Caspase-8-deficient Jurkat cells, Bcl-xL overexpression, dominant-negative caspase-9, caspase-3-lacking MCF7 cells with caspase-3 transfection, western blotting","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic tools (KO cells, dominant-negative constructs, reconstitution) and orthogonal readouts; clearly distinguishes two CASP8 activation contexts","pmids":["11030145"],"is_preprint":false},{"year":2007,"finding":"The CASP8 prodomain can be autocleavaged between its two tandem DEDs (at Asp129 by caspase-8 itself), generating a DEDa fragment. DEDa translocates to the nucleus via association with ERK1/2, interacts with TOPORS (a p53/topoisomerase I binding protein), and displaces p53 from TOPORS to allow p53-mediated stimulation of CASP8 gene expression, forming a positive feedback loop during apoptosis.","method":"In vitro cleavage assay, co-immunoprecipitation, nuclear fractionation, RNA interference of ERK1/2, reporter assays, confocal microscopy","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, nuclear fractionation, RNAi, and reporter assays in single lab; novel non-canonical mechanism","pmids":["17290218"],"is_preprint":false},{"year":2014,"finding":"The C-terminal domain of c-FLIP(L) specifically inhibits the interaction of the CASP8 prodomain with the RIP1 death domain, thereby regulating CASP8-dependent NF-κB activation induced by FasL. The prodomain of CASP8 is sufficient to interact with RIP1 and to mediate NF-κB activation; c-FLIP(p43) (lacking the C-terminal domain) does not inhibit this interaction.","method":"Co-immunoprecipitation, mutant c-FLIP constructs (c-FLIPD376N, c-FLIPp43), HEK 293 cells lacking caspase-8, caspase inhibitor (zVAD), NF-κB reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IPs with domain mutants and genetic variants, single lab","pmids":["24398693"],"is_preprint":false},{"year":2021,"finding":"CASP8 induces PD-L1 degradation by upregulating TNFAIP3 (A20), a ubiquitin-editing enzyme that promotes PD-L1 ubiquitination. Knockdown of CASP8 in melanoma cells increases PD-L1 levels and promotes tumor progression in an immune system-dependent manner.","method":"shRNA knockdown of CASP8 in mouse melanoma cells, in vivo tumor growth assays, western blot/ubiquitination assays for PD-L1, conditional NK-cell-specific CASP8 knockout mice (Ncr1iCre/+ Casp8fl/fl)","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo KD/KO approaches with mechanistic readouts, single lab","pmids":["33934451"],"is_preprint":false},{"year":2024,"finding":"TNF/IFNγ-induced CASP8 activation and cancer cell death require IRF1-mediated transcriptional upregulation of CASP8 (and CYLD). Additionally, ELAVL1 (HuR) binds CASP8 mRNA and stabilizes it under both basal and IFNγ-stimulated conditions; loss of ELAVL1 reduces CASP8 levels and blocks death receptor-initiated caspase-8-dependent apoptosis (from TNF, TRAIL, and FasL).","method":"Genetic screen, RNA immunoprecipitation (ELAVL1-CASP8 mRNA binding), IRF1 ChIP/transcription assays, mRNA stability assays, genetic KO of ELAVL1, caspase activity assays, cancer cell death assays","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic screen plus multiple mechanistic follow-up assays; single lab with orthogonal methods","pmids":["38319288"],"is_preprint":false},{"year":2023,"finding":"FYCO1 (an autophagic vesicle transport protein) is a direct substrate of activated CASP8. CASP8 cleaves FYCO1 at aspartate 1306, releasing the C-terminal GOLD domain and inactivating FYCO1 function. Loss of FYCO1 sensitizes cells to TRAIL-induced apoptosis by stabilizing the DISC and impairing TNFRSF10B (TRAIL-R2/DR5) transport to lysosomes.","method":"Affinity purification/co-immunoprecipitation with activated CASP8, in vitro cleavage assay with mutagenesis of cleavage site (D1306), CRISPR/shRNA KO of FYCO1, DISC immunoprecipitation, receptor trafficking assays","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro cleavage with site-specific mutagenesis plus co-IP and functional genetic KO; multiple orthogonal methods in one study","pmids":["37418591"],"is_preprint":false},{"year":2019,"finding":"Deletion of epithelial Casp8 in mice (Casp8∆IEC) results in ileocolitis, epithelial barrier dysfunction, reduced expression of Muc2 and defensins, and impaired body weight gain, establishing a required role for CASP8 in intestinal epithelial homeostasis. The intestinal phenotype is consistent with earlier work showing cFlip-regulated constitutive CASP8 activation.","method":"Conditional intestinal epithelial-specific CASP8 knockout mice, histology, endoscopy, gene expression analysis of barrier genes","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean conditional KO with defined phenotypic readouts; single lab, corroborates Wittkopf et al. 2013","pmids":["31411503"],"is_preprint":false},{"year":2013,"finding":"cFlip expression in intestinal epithelial cells is required for constitutive low-level activation of caspase-8 under steady-state conditions, which promotes cell survival. Conditional deletion of cFlip in adult intestinal epithelium leads to massive CASP8- and CASP3-dependent apoptosis and fatal intestinal destruction within days; cell death requires death receptor ligands (TNF-α, CD95L) and is independent of RIP3.","method":"Conditional (inducible and permanent) intestinal epithelial knockout of cFlip, caspase-8 and caspase-3 activity assays, histology, death receptor ligand neutralization experiments","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent conditional KO models (inducible and permanent), multiple mechanistic readouts, death receptor dependence confirmed","pmids":["24036366"],"is_preprint":false},{"year":2007,"finding":"A 6-nucleotide deletion in the CASP8 promoter (-652 6N del) destroys an Sp1 binding site, decreases CASP8 transcription, and results in lower caspase-8 activity and reduced activation-induced T-cell death in response to cancer cell antigens.","method":"Promoter reporter assay, Sp1 binding site analysis, biochemical caspase-8 activity measurement in T lymphocytes from variant carriers, case-control genotyping","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assay plus functional caspase-8 activity in human lymphocytes; mechanistic follow-up supports the regulatory claim","pmids":["17450141"],"is_preprint":false},{"year":2002,"finding":"Cleavage-site-directed antibodies demonstrate that CASP8/FLICE cleavage at the DISC and subsequent cleavage of its substrate FLIP (at LEVD376↓G) can be monitored in situ. Fas stimulation in IFN-γ-treated U937 cells markedly increases CASP8 processing; vitamin D3- or retinoic acid-differentiated Fas-resistant U937 cells show inhibited CASP8 processing, placing CASP8 activation upstream of changes in Fas sensitivity.","method":"Cleavage-site-directed antibodies, immunoblotting, flow cytometry, confocal microscopy, in vitro cleavage assays with GST-FLIP","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — novel cleavage-site antibodies validated in vitro and in cell-based assays; single lab, multiple detection methods","pmids":["12097160"],"is_preprint":false}],"current_model":"CASP8 is an initiator cysteine protease recruited via its N-terminal death effector domains (DEDs) to the death-inducing signaling complex (DISC) formed at activated death receptors (Fas/CD95, TNFR1, TRAIL-Rs), where it undergoes two-step autoproteolytic activation to generate the active p18/p10 heterotetramer; active CASP8 then directly cleaves and activates downstream effector caspases (-3, -6, -7) and the BH3-only protein Bid to amplify apoptosis through the mitochondrial pathway, while in drug-induced (mitochondrial) apoptosis it acts instead as an amplifying executioner downstream of caspase-3; non-apoptotic functions include NF-κB activation via RIP1 interaction (regulated by c-FLIP(L) C-terminal domain), nuclear translocation of its autocleavage product DEDa to sustain CASP8 transcription, upregulation of A20 to promote PD-L1 ubiquitination and degradation, and cleavage of FYCO1 to inactivate vesicular transport of death receptors; its expression is regulated transcriptionally by IRF1 and post-transcriptionally by ELAVL1-mediated mRNA stabilization, and in the intestinal epithelium constitutive low-level CASP8 activation (controlled by cFLIP) is required for epithelial homeostasis and barrier integrity."},"narrative":{"mechanistic_narrative":"CASP8 is an initiator cysteine protease that serves as the apical enzymatic trigger of death receptor-induced apoptosis, recruited through its N-terminal death effector domains to FADD/MORT1 at the death-inducing signaling complex (DISC) of Fas/CD95 and TNF receptors [PMID:8681376, PMID:9184224]. At the DISC, CASP8 is activated by a two-step autoproteolytic mechanism — an initial cleavage generating p43/p12 followed by release of the active-site p18 fragment — and this activation strictly requires DISC association and is blocked by IETD-type peptide inhibitors [PMID:9184224]. Once active, recombinant CASP8 directly processes and activates the full set of downstream ICE/CED-3-family caspases (CASP3, CASP6, CASP7 and others) and is inhibited by the serpin CrmA, establishing it as the most upstream protease of the cascade [PMID:8962078, PMID:9006941]; genetic loss in Jurkat cells abolishes Fas-induced apoptosis and downstream caspase and stress-kinase activation, confirming its essential apical role [PMID:9740801]. CASP8 function is context-dependent: in drug-induced (mitochondrial) apoptosis it is not the initiator but acts as an amplifying executioner downstream of mitochondria and caspase-3 [PMID:10216102, PMID:11030145]. Beyond apoptosis, CASP8 participates in non-death signaling — its prodomain interacts with RIP1 to drive NF-κB activation under control of the c-FLIP(L) C-terminal domain [PMID:24398693], an autocleaved DEDa prodomain fragment translocates to the nucleus to sustain CASP8 transcription via TOPORS/p53 [PMID:17290218], and active CASP8 cleaves the vesicular transport protein FYCO1 to modulate death receptor trafficking and TRAIL sensitivity [PMID:37418591]. CASP8 levels are set transcriptionally by IRF1 and Sp1 and post-transcriptionally by ELAVL1-mediated mRNA stabilization [PMID:38319288, PMID:17450141]. In the intestinal epithelium, constitutive low-level CASP8 activation controlled by cFLIP is required for homeostasis and barrier integrity, and its loss causes ileocolitis and barrier dysfunction [PMID:31411503, PMID:24036366].","teleology":[{"year":1996,"claim":"Established the molecular identity of CASP8 and connected death receptor engagement to a proteolytic effector by showing it binds FADD via its prodomain and triggers cell death downstream of Fas and TNFR.","evidence":"Yeast two-hybrid cloning, co-immunoprecipitation, and overexpression-induced death assays","pmids":["8681376"],"confidence":"High","gaps":["Did not define the activation mechanism or direct downstream substrates","Overexpression-driven death may not reflect endogenous kinetics"]},{"year":1996,"claim":"Defined CASP8 as a self-processing two-subunit enzyme and placed it atop the protease cascade by showing it directly cleaves all known ICE/CED-3 caspases in vitro and is blocked by CrmA.","evidence":"Bacterial recombinant enzyme, in vitro substrate cleavage, N-terminal sequencing, CrmA inhibition","pmids":["8962078"],"confidence":"High","gaps":["In vitro substrate promiscuity may not reflect physiological selectivity","Did not address how activation is gated in cells"]},{"year":1997,"claim":"Resolved how CASP8 is activated in cells, showing a two-step DISC-localized cleavage requiring DED-mediated FADD binding, distinguishing receptor-proximal activation from cytosolic processing.","evidence":"DISC fractionation/immunoprecipitation, cleavage-site antibodies, peptide inhibitor and mass spectrometry studies","pmids":["9184224"],"confidence":"High","gaps":["Structural basis of dimerization-induced activation not defined","Did not quantify proximity-induced versus autocatalytic contributions"]},{"year":1997,"claim":"Confirmed in a defined cell-free system that CASP8 directly initiates the downstream caspase cascade, consolidating its apical position.","evidence":"Cell-free reconstitution with recombinant FLICE and caspase zymogens plus CrmA inhibition","pmids":["9006941"],"confidence":"High","gaps":["Did not establish which caspases are direct physiological substrates in vivo"]},{"year":1997,"claim":"Clarified which CASP8 isoforms operate physiologically, showing only caspase-8/a and /b are detectably expressed and are recruited to and activated at the DISC.","evidence":"Monoclonal antibody panel, western blotting, DISC immunoprecipitation, activation kinetics","pmids":["9341131"],"confidence":"Medium","gaps":["Antibody detection from a single lab","Function of remaining isoforms unresolved"]},{"year":1998,"claim":"Provided genetic proof of essentiality, showing CASP8-deficient cells lose Fas apoptosis and downstream caspase/kinase activation, rescued by complementation.","evidence":"Caspase-8-deficient Jurkat line with wild-type complementation and pathway readouts","pmids":["9740801"],"confidence":"High","gaps":["Did not separate apoptotic from non-apoptotic CASP8 requirements","Cell-line-specific epistasis"]},{"year":1999,"claim":"Revealed a receptor-independent activation context, showing anticancer drugs activate CASP8 without CD95 ligand engagement or functional FADD.","evidence":"CD95-resistant cells, dominant-negative FADD, p18 western blotting, inhibitor studies","pmids":["10216102"],"confidence":"High","gaps":["Did not define whether CASP8 was initiator or amplifier in this context"]},{"year":2000,"claim":"Reassigned CASP8's role in drug-induced apoptosis as an amplifying executioner downstream of mitochondria and caspase-3 rather than the initiator.","evidence":"CASP8-deficient Jurkat, Bcl-xL overexpression, dominant-negative caspase-9, caspase-3-null MCF7 reconstitution","pmids":["11030145"],"confidence":"High","gaps":["Molecular trigger of CASP8 cleavage downstream of caspase-3 not detailed"]},{"year":2002,"claim":"Enabled in situ monitoring of CASP8 and FLIP cleavage and linked CASP8 processing to differentiation-dependent Fas sensitivity.","evidence":"Cleavage-site-directed antibodies, immunoblotting, flow cytometry, in vitro GST-FLIP cleavage","pmids":["12097160"],"confidence":"Medium","gaps":["Single-lab antibody reagents","Mechanism linking differentiation to Fas resistance not fully defined"]},{"year":2007,"claim":"Uncovered a non-apoptotic transcriptional feedback role, showing an autocleaved DEDa prodomain fragment enters the nucleus and sustains CASP8 expression via TOPORS/p53.","evidence":"In vitro cleavage, co-IP, nuclear fractionation, ERK1/2 RNAi, reporter assays, confocal microscopy","pmids":["17290218"],"confidence":"Medium","gaps":["Single-lab mechanism","Physiological significance of the feedback loop in vivo unclear"]},{"year":2007,"claim":"Established a functional promoter variant controlling CASP8 expression, showing a 6N deletion disrupting an Sp1 site lowers transcription, caspase-8 activity, and activation-induced T-cell death.","evidence":"Promoter reporter assays, Sp1 site analysis, caspase activity in carrier lymphocytes, case-control genotyping","pmids":["17450141"],"confidence":"Medium","gaps":["Causal disease link beyond association not established here"]},{"year":2013,"claim":"Defined a homeostatic survival role, showing cFLIP-controlled constitutive low-level CASP8 activation sustains intestinal epithelium and that cFLIP loss causes fatal CASP8/CASP3-dependent apoptosis requiring death receptor ligands.","evidence":"Inducible and permanent epithelial cFlip knockout mice, caspase activity assays, ligand neutralization","pmids":["24036366"],"confidence":"High","gaps":["Molecular basis distinguishing survival from death-inducing CASP8 activation unresolved"]},{"year":2019,"claim":"Demonstrated an intrinsic epithelial requirement for CASP8 in barrier integrity, with epithelial deletion causing ileocolitis and reduced Muc2/defensin expression.","evidence":"Intestinal epithelial-specific CASP8 knockout mice, histology, endoscopy, barrier gene expression","pmids":["31411503"],"confidence":"Medium","gaps":["Mechanism linking CASP8 loss to mucin/defensin reduction not defined","Single lab"]},{"year":2021,"claim":"Linked CASP8 to anti-tumor immunity by showing it drives PD-L1 degradation via A20 (TNFAIP3) upregulation, with knockdown raising PD-L1 and promoting immune-dependent tumor growth.","evidence":"shRNA knockdown in melanoma, in vivo tumor assays, PD-L1 ubiquitination assays, NK-cell-specific conditional knockout","pmids":["33934451"],"confidence":"Medium","gaps":["Whether protease activity or scaffolding drives A20 upregulation unclear","Single lab"]},{"year":2023,"claim":"Identified FYCO1 as a direct CASP8 substrate, showing cleavage at D1306 inactivates vesicular transport and modulates DISC stability and TRAIL receptor trafficking.","evidence":"Affinity purification, in vitro cleavage with D1306 mutagenesis, CRISPR/shRNA knockout, DISC IP, receptor trafficking assays","pmids":["37418591"],"confidence":"High","gaps":["Generality of FYCO1 cleavage across cell types not established"]},{"year":2024,"claim":"Defined dual regulation of CASP8 abundance, showing IRF1-driven transcription and ELAVL1-mediated mRNA stabilization are required for death receptor-initiated apoptosis.","evidence":"Genetic screen, RNA-IP, IRF1 ChIP, mRNA stability assays, ELAVL1 knockout, caspase/death assays","pmids":["38319288"],"confidence":"Medium","gaps":["Interplay between transcriptional and post-transcriptional control not quantified","Single lab"]},{"year":null,"claim":"How the same enzyme switches between constitutive survival signaling, non-apoptotic NF-κB/transcriptional roles, and full apoptotic execution at the molecular level remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural/biochemical switch defined for survival versus death outputs","In vivo substrate repertoire beyond caspases, Bid, FYCO1, and FLIP incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,2,3,12]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,2,3]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9,10]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,0]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,2,5,7]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,10]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,11]}],"complexes":["DISC"],"partners":["FADD","RIP1","TOPORS","FYCO1","ELAVL1","CFLAR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q14790","full_name":"Caspase-8","aliases":["Apoptotic cysteine protease","Apoptotic protease Mch-5","CAP4","FADD-homologous ICE/ced-3-like protease","FADD-like ICE","FLICE","ICE-like apoptotic protease 5","MORT1-associated ced-3 homolog","MACH"],"length_aa":479,"mass_kda":55.4,"function":"Thiol protease that plays a key role in programmed cell death by acting as a molecular switch for apoptosis, necroptosis and pyroptosis, and is required to prevent tissue damage during embryonic development and adulthood (PubMed:23516580, PubMed:35338844, PubMed:35446120, PubMed:8681376, PubMed:8681377, PubMed:8962078, PubMed:9006941, PubMed:9184224). Initiator protease that induces extrinsic apoptosis by mediating cleavage and activation of effector caspases responsible for FAS/CD95-mediated and TNFRSF1A-induced cell death (PubMed:23516580, PubMed:35338844, PubMed:35446120, PubMed:8681376, PubMed:8681377, PubMed:8962078, PubMed:9006941, PubMed:9184224). Cleaves and activates effector caspases CASP3, CASP4, CASP6, CASP7, CASP9 and CASP10 (PubMed:16916640, PubMed:8962078, PubMed:9006941). Binding to the adapter molecule FADD recruits it to either receptor FAS/TNFRSF6 or TNFRSF1A (PubMed:8681376, PubMed:8681377). The resulting aggregate called the death-inducing signaling complex (DISC) performs CASP8 proteolytic activation (PubMed:9184224). The active dimeric enzyme is then liberated from the DISC and free to activate downstream apoptotic proteases (PubMed:9184224). Proteolytic fragments of the N-terminal propeptide (termed CAP3, CAP5 and CAP6) are likely retained in the DISC (PubMed:9184224). Also cleaves and activates BID, thereby promoting cytochrome C release from mitochrondria (By similarity). In addition to extrinsic apoptosis, also acts as a negative regulator of necroptosis: acts by cleaving RIPK1 at 'Asp-324', which is crucial to inhibit RIPK1 kinase activity, limiting TNF-induced apoptosis, necroptosis and inflammatory response (PubMed:31827280, PubMed:31827281). Also able to initiate pyroptosis by mediating cleavage and activation of gasdermin-C and -D (GSDMC and GSDMD, respectively): gasdermin cleavage promotes release of the N-terminal moiety that binds to membranes and forms pores, triggering pyroptosis (PubMed:32929201, PubMed:34012073). Initiates pyroptosis following inactivation of MAP3K7/TAK1 (By similarity). Also acts as a regulator of innate immunity by mediating cleavage and inactivation of N4BP1 downstream of TLR3 or TLR4, thereby promoting cytokine production (By similarity). May participate in the Granzyme B (GZMB) cell death pathways (PubMed:8755496). Cleaves PARP1 and PARP2 (PubMed:8681376). Independent of its protease activity, promotes cell migration following phosphorylation at Tyr-380 (PubMed:18216014, PubMed:27109099) Lacks the catalytic site and may interfere with the pro-apoptotic activity of the complex Lacks the catalytic site and may interfere with the pro-apoptotic activity of the complex Lacks the catalytic site and may interfere with the pro-apoptotic activity of the complex (Probable). Acts as an inhibitor of the caspase cascade (PubMed:12010809) Lacks the catalytic site and may interfere with the pro-apoptotic activity of the complex","subcellular_location":"Cytoplasm; Nucleus; Cell projection, lamellipodium","url":"https://www.uniprot.org/uniprotkb/Q14790/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CASP8","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CASP8","total_profiled":1310},"omim":[{"mim_id":"620795","title":"AUTOINFLAMMATION WITH EPISODIC FEVER AND IMMUNE DYSREGULATION; AIFID","url":"https://www.omim.org/entry/620795"},{"mim_id":"620290","title":"TRANSMEMBRANE PROTEIN 219; TMEM219","url":"https://www.omim.org/entry/620290"},{"mim_id":"619516","title":"BIFUNCTIONAL APOPTOSIS REGULATOR; BFAR","url":"https://www.omim.org/entry/619516"},{"mim_id":"619138","title":"NEDD4-BINDING PROTEIN 1; N4BP1","url":"https://www.omim.org/entry/619138"},{"mim_id":"618425","title":"NEURODEVELOPMENTAL DISORDER WITH IMPAIRED SPEECH AND HYPERKINETIC MOVEMENTS; NEDISHM","url":"https://www.omim.org/entry/618425"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Mitochondria","reliability":"Uncertain"},{"location":"Cytosol","reliability":"Uncertain"},{"location":"Centriolar satellite","reliability":"Additional"},{"location":"Connecting piece","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":44.1}],"url":"https://www.proteinatlas.org/search/CASP8"},"hgnc":{"alias_symbol":["MCH5","MACH","FLICE","Casp-8"],"prev_symbol":[]},"alphafold":{"accession":"Q14790","domains":[{"cath_id":"1.10.533.10","chopping":"2-98","consensus_level":"high","plddt":86.088,"start":2,"end":98},{"cath_id":"1.10.533.10","chopping":"100-183","consensus_level":"high","plddt":82.4757,"start":100,"end":183},{"cath_id":"3.40.50.1460","chopping":"234-366_394-468","consensus_level":"high","plddt":92.2848,"start":234,"end":468}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14790","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14790-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14790-F1-predicted_aligned_error_v6.png","plddt_mean":81.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CASP8","jax_strain_url":"https://www.jax.org/strain/search?query=CASP8"},"sequence":{"accession":"Q14790","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14790.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14790/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14790"}},"corpus_meta":[{"pmid":"19446902","id":"PMC_19446902","title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.","date":"2009","source":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19446902","citation_count":2266,"is_preprint":false},{"pmid":"8681376","id":"PMC_8681376","title":"Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8681376","citation_count":2050,"is_preprint":false},{"pmid":"10768432","id":"PMC_10768432","title":"Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.","date":"2000","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10768432","citation_count":1846,"is_preprint":false},{"pmid":"9184224","id":"PMC_9184224","title":"FLICE is activated by association with the CD95 death-inducing signaling complex (DISC).","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9184224","citation_count":1023,"is_preprint":false},{"pmid":"8962078","id":"PMC_8962078","title":"Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8962078","citation_count":489,"is_preprint":false},{"pmid":"9740801","id":"PMC_9740801","title":"Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade.","date":"1998","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9740801","citation_count":452,"is_preprint":false},{"pmid":"21684027","id":"PMC_21684027","title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.","date":"2011","source":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21684027","citation_count":444,"is_preprint":false},{"pmid":"9211860","id":"PMC_9211860","title":"I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9211860","citation_count":369,"is_preprint":false},{"pmid":"9341131","id":"PMC_9341131","title":"FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9341131","citation_count":356,"is_preprint":false},{"pmid":"10510092","id":"PMC_10510092","title":"The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10510092","citation_count":339,"is_preprint":false},{"pmid":"9006941","id":"PMC_9006941","title":"FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9006941","citation_count":305,"is_preprint":false},{"pmid":"33515668","id":"PMC_33515668","title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.","date":"2021","source":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33515668","citation_count":279,"is_preprint":false},{"pmid":"10510093","id":"PMC_10510093","title":"Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10510093","citation_count":275,"is_preprint":false},{"pmid":"10216102","id":"PMC_10216102","title":"Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10216102","citation_count":268,"is_preprint":false},{"pmid":"9271594","id":"PMC_9271594","title":"A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9271594","citation_count":252,"is_preprint":false},{"pmid":"11030145","id":"PMC_11030145","title":"Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11030145","citation_count":226,"is_preprint":false},{"pmid":"17450141","id":"PMC_17450141","title":"A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17450141","citation_count":219,"is_preprint":false},{"pmid":"11830587","id":"PMC_11830587","title":"The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11830587","citation_count":202,"is_preprint":false},{"pmid":"28218919","id":"PMC_28218919","title":"Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.","date":"2017","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28218919","citation_count":191,"is_preprint":false},{"pmid":"10232592","id":"PMC_10232592","title":"Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis.","date":"1999","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10232592","citation_count":176,"is_preprint":false},{"pmid":"18288942","id":"PMC_18288942","title":"Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.","date":"2008","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/18288942","citation_count":150,"is_preprint":false},{"pmid":"17003335","id":"PMC_17003335","title":"Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets.","date":"2006","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/17003335","citation_count":138,"is_preprint":false},{"pmid":"19932761","id":"PMC_19932761","title":"Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer.","date":"2009","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19932761","citation_count":126,"is_preprint":false},{"pmid":"12861043","id":"PMC_12861043","title":"Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma.","date":"2003","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12861043","citation_count":120,"is_preprint":false},{"pmid":"15258564","id":"PMC_15258564","title":"Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15258564","citation_count":115,"is_preprint":false},{"pmid":"11181697","id":"PMC_11181697","title":"FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis.","date":"2001","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11181697","citation_count":104,"is_preprint":false},{"pmid":"22309778","id":"PMC_22309778","title":"Cellular FLICE-like inhibitory proteins (c-FLIPs): fine-tuners of life and death decisions.","date":"2012","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22309778","citation_count":97,"is_preprint":false},{"pmid":"14563855","id":"PMC_14563855","title":"The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14563855","citation_count":94,"is_preprint":false},{"pmid":"15096587","id":"PMC_15096587","title":"Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15096587","citation_count":89,"is_preprint":false},{"pmid":"9624166","id":"PMC_9624166","title":"ERICE, a novel FLICE-activatable caspase.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9624166","citation_count":89,"is_preprint":false},{"pmid":"12885274","id":"PMC_12885274","title":"Cellular FLICE-inhibitory protein: an attractive therapeutic target?","date":"2003","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/12885274","citation_count":87,"is_preprint":false},{"pmid":"17545522","id":"PMC_17545522","title":"Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17545522","citation_count":81,"is_preprint":false},{"pmid":"9931493","id":"PMC_9931493","title":"Structure and chromosome localization of the human CASP8 gene.","date":"1999","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9931493","citation_count":79,"is_preprint":false},{"pmid":"21454681","id":"PMC_21454681","title":"Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21454681","citation_count":78,"is_preprint":false},{"pmid":"16043518","id":"PMC_16043518","title":"Cellular FLICE-inhibitory protein is required for T cell survival and cycling.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16043518","citation_count":74,"is_preprint":false},{"pmid":"20154269","id":"PMC_20154269","title":"BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.","date":"2010","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20154269","citation_count":74,"is_preprint":false},{"pmid":"11406564","id":"PMC_11406564","title":"Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11406564","citation_count":74,"is_preprint":false},{"pmid":"20150411","id":"PMC_20150411","title":"MULTICOM: a multi-level combination approach to protein structure prediction and its assessments in CASP8.","date":"2010","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20150411","citation_count":72,"is_preprint":false},{"pmid":"12406869","id":"PMC_12406869","title":"The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12406869","citation_count":67,"is_preprint":false},{"pmid":"24036366","id":"PMC_24036366","title":"Cellular FLICE-like inhibitory protein secures intestinal epithelial cell survival and immune homeostasis by regulating caspase-8.","date":"2013","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/24036366","citation_count":66,"is_preprint":false},{"pmid":"15507484","id":"PMC_15507484","title":"FLICE/caspase-8 activation triggers anoikis induced by beta1-integrin blockade in human keratinocytes.","date":"2004","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/15507484","citation_count":65,"is_preprint":false},{"pmid":"17145853","id":"PMC_17145853","title":"Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17145853","citation_count":65,"is_preprint":false},{"pmid":"19731372","id":"PMC_19731372","title":"The other 90% of the protein: assessment beyond the Calphas for CASP8 template-based and high-accuracy models.","date":"2009","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/19731372","citation_count":64,"is_preprint":false},{"pmid":"11384965","id":"PMC_11384965","title":"Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11384965","citation_count":63,"is_preprint":false},{"pmid":"10975811","id":"PMC_10975811","title":"Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10975811","citation_count":60,"is_preprint":false},{"pmid":"11439165","id":"PMC_11439165","title":"Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms.","date":"2001","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11439165","citation_count":59,"is_preprint":false},{"pmid":"15788647","id":"PMC_15788647","title":"Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas.","date":"2005","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15788647","citation_count":55,"is_preprint":false},{"pmid":"10623660","id":"PMC_10623660","title":"Expression of cellular FLICE-inhibitory protein in human coronary arteries and in a rat vascular injury model.","date":"2000","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10623660","citation_count":54,"is_preprint":false},{"pmid":"22672670","id":"PMC_22672670","title":"MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma.","date":"2012","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22672670","citation_count":52,"is_preprint":false},{"pmid":"22202974","id":"PMC_22202974","title":"Cellular FLICE-inhibitory protein protects against cardiac remodelling after myocardial infarction.","date":"2011","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/22202974","citation_count":48,"is_preprint":false},{"pmid":"22582174","id":"PMC_22582174","title":"Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis.","date":"2012","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22582174","citation_count":46,"is_preprint":false},{"pmid":"23252466","id":"PMC_23252466","title":"Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer.","date":"2012","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/23252466","citation_count":46,"is_preprint":false},{"pmid":"16579975","id":"PMC_16579975","title":"Cellular FLICE-like inhibitory protein (c-FLIP): a novel target for Taxol-induced apoptosis.","date":"2006","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16579975","citation_count":46,"is_preprint":false},{"pmid":"17064406","id":"PMC_17064406","title":"Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.","date":"2006","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17064406","citation_count":46,"is_preprint":false},{"pmid":"24398693","id":"PMC_24398693","title":"The C-terminal domain of the long form of cellular FLICE-inhibitory protein (c-FLIPL) inhibits the interaction of the caspase 8 prodomain with the receptor-interacting protein 1 (RIP1) death domain and regulates caspase 8-dependent nuclear factor κB (NF-κB) activation.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24398693","citation_count":44,"is_preprint":false},{"pmid":"14561765","id":"PMC_14561765","title":"Molecular genetic analysis of human herpes virus 8-encoded viral FLICE inhibitory protein-induced NF-kappaB activation.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14561765","citation_count":43,"is_preprint":false},{"pmid":"16441226","id":"PMC_16441226","title":"The role of cellular FLICE inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer.","date":"2006","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/16441226","citation_count":42,"is_preprint":false},{"pmid":"30670829","id":"PMC_30670829","title":"Suppression of the SAP18/HDAC1 complex by targeting TRIM56 and Nanog is essential for oncogenic viral FLICE-inhibitory protein-induced acetylation of p65/RelA, NF-κB activation, and promotion of cell invasion and angiogenesis.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/30670829","citation_count":40,"is_preprint":false},{"pmid":"32792491","id":"PMC_32792491","title":"Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32792491","citation_count":39,"is_preprint":false},{"pmid":"15466406","id":"PMC_15466406","title":"FLICE-like inhibitory protein (FLIP) protects against apoptosis and suppresses NF-kappaB activation induced by bacterial lipopolysaccharide.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15466406","citation_count":39,"is_preprint":false},{"pmid":"25168388","id":"PMC_25168388","title":"Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25168388","citation_count":38,"is_preprint":false},{"pmid":"20176653","id":"PMC_20176653","title":"CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies.","date":"2010","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20176653","citation_count":36,"is_preprint":false},{"pmid":"19203830","id":"PMC_19203830","title":"Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer.","date":"2009","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19203830","citation_count":35,"is_preprint":false},{"pmid":"33934451","id":"PMC_33934451","title":"Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/33934451","citation_count":33,"is_preprint":false},{"pmid":"20975036","id":"PMC_20975036","title":"Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice.","date":"2010","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/20975036","citation_count":31,"is_preprint":false},{"pmid":"20978178","id":"PMC_20978178","title":"Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.","date":"2010","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20978178","citation_count":31,"is_preprint":false},{"pmid":"20086182","id":"PMC_20086182","title":"The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck.","date":"2010","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/20086182","citation_count":31,"is_preprint":false},{"pmid":"21714991","id":"PMC_21714991","title":"Polymorphisms in the CASP8 gene and the risk of epithelial ovarian cancer.","date":"2011","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21714991","citation_count":30,"is_preprint":false},{"pmid":"19603487","id":"PMC_19603487","title":"Target domain definition and classification in CASP8.","date":"2009","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/19603487","citation_count":29,"is_preprint":false},{"pmid":"17200356","id":"PMC_17200356","title":"Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17200356","citation_count":28,"is_preprint":false},{"pmid":"19160091","id":"PMC_19160091","title":"Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.","date":"2009","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/19160091","citation_count":26,"is_preprint":false},{"pmid":"26740556","id":"PMC_26740556","title":"Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26740556","citation_count":25,"is_preprint":false},{"pmid":"19722263","id":"PMC_19722263","title":"Protein structure prediction center in CASP8.","date":"2009","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/19722263","citation_count":25,"is_preprint":false},{"pmid":"11086061","id":"PMC_11086061","title":"Enhanced expression of Fas-associated death domain-like IL-1-converting enzyme (FLICE)-inhibitory protein induces resistance to Fas-mediated apoptosis in activated mast cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11086061","citation_count":25,"is_preprint":false},{"pmid":"17290218","id":"PMC_17290218","title":"Death effector domain DEDa, a self-cleaved product of caspase-8/Mch5, translocates to the nucleus by binding to ERK1/2 and upregulates procaspase-8 expression via a p53-dependent mechanism.","date":"2007","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17290218","citation_count":24,"is_preprint":false},{"pmid":"14637155","id":"PMC_14637155","title":"Long form of cellular FLICE-inhibitory protein interacts with Daxx and prevents Fas-induced JNK activation.","date":"2003","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14637155","citation_count":24,"is_preprint":false},{"pmid":"16014121","id":"PMC_16014121","title":"Expression of cellular FLICE/caspase-8 inhibitory protein is associated with malignant potential in endometrial carcinoma.","date":"2005","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/16014121","citation_count":24,"is_preprint":false},{"pmid":"22056502","id":"PMC_22056502","title":"Fine-mapping CASP8 risk variants in breast cancer.","date":"2011","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22056502","citation_count":23,"is_preprint":false},{"pmid":"23317270","id":"PMC_23317270","title":"shRNA mediated RHOXF1 silencing influences expression of BCL2 but not CASP8 in MCF-7 and MDA-MB-231 cell lines.","date":"2012","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/23317270","citation_count":23,"is_preprint":false},{"pmid":"25333816","id":"PMC_25333816","title":"Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation.","date":"2014","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/25333816","citation_count":23,"is_preprint":false},{"pmid":"34234270","id":"PMC_34234270","title":"Resveratrol promotes skin wound healing by regulating the miR-212/CASP8 axis.","date":"2021","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34234270","citation_count":22,"is_preprint":false},{"pmid":"20157476","id":"PMC_20157476","title":"Analysis of CASP8 targets, predictions and assessment methods.","date":"2009","source":"Database : the journal of biological databases and curation","url":"https://pubmed.ncbi.nlm.nih.gov/20157476","citation_count":22,"is_preprint":false},{"pmid":"33828176","id":"PMC_33828176","title":"Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33828176","citation_count":21,"is_preprint":false},{"pmid":"23371318","id":"PMC_23371318","title":"ERK controls epithelial cell death receptor signalling and cellular FLICE-like inhibitory protein (c-FLIP) in ulcerative colitis.","date":"2013","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/23371318","citation_count":21,"is_preprint":false},{"pmid":"21726997","id":"PMC_21726997","title":"Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells.","date":"2011","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/21726997","citation_count":21,"is_preprint":false},{"pmid":"29165042","id":"PMC_29165042","title":"Suppressed translation as a mechanism of initiation of CASP8 (caspase 8)-dependent apoptosis in autophagy-deficient NSCLC cells under nutrient limitation.","date":"2018","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/29165042","citation_count":21,"is_preprint":false},{"pmid":"32442541","id":"PMC_32442541","title":"Association of CASP8 polymorphisms and cancer susceptibility: A meta-analysis.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32442541","citation_count":20,"is_preprint":false},{"pmid":"36863647","id":"PMC_36863647","title":"Rosmarinic acid decreases viability, inhibits migration and modulates expression of apoptosis-related CASP8/CASP3/NLRP3 genes in human metastatic melanoma cells.","date":"2023","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/36863647","citation_count":20,"is_preprint":false},{"pmid":"18466417","id":"PMC_18466417","title":"Cardioprotective effect of vanadyl sulfate on ischemia/reperfusion-induced injury in rat heart in vivo is mediated by activation of protein kinase B and induction of FLICE-inhibitory protein.","date":"2008","source":"Cardiovascular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/18466417","citation_count":20,"is_preprint":false},{"pmid":"22843554","id":"PMC_22843554","title":"Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.","date":"2012","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/22843554","citation_count":19,"is_preprint":false},{"pmid":"15832422","id":"PMC_15832422","title":"Expression of cellular FLICE-inhibitory protein and its association with p53 mutation in colon cancer.","date":"2005","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15832422","citation_count":19,"is_preprint":false},{"pmid":"29107687","id":"PMC_29107687","title":"MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29107687","citation_count":19,"is_preprint":false},{"pmid":"38319288","id":"PMC_38319288","title":"TNF and IFNγ-induced cell death requires IRF1 and ELAVL1 to promote CASP8 expression.","date":"2024","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38319288","citation_count":18,"is_preprint":false},{"pmid":"37515387","id":"PMC_37515387","title":"Medicarpin suppresses proliferation and triggeres apoptosis by upregulation of BID, BAX, CASP3, CASP8, and CYCS in glioblastoma.","date":"2023","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/37515387","citation_count":18,"is_preprint":false},{"pmid":"31411503","id":"PMC_31411503","title":"Deletion of the Casp8 gene in mice results in ileocolitis, gut barrier dysfunction, and malassimilation, which can be partially attenuated by inulin or sodium butyrate.","date":"2019","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31411503","citation_count":18,"is_preprint":false},{"pmid":"37418591","id":"PMC_37418591","title":"The autophagic protein FYCO1 controls TNFRSF10/TRAIL receptor induced apoptosis and is inactivated by CASP8 (caspase 8).","date":"2023","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/37418591","citation_count":17,"is_preprint":false},{"pmid":"23313206","id":"PMC_23313206","title":"The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis.","date":"2013","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/23313206","citation_count":17,"is_preprint":false},{"pmid":"17940865","id":"PMC_17940865","title":"CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk.","date":"2007","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/17940865","citation_count":17,"is_preprint":false},{"pmid":"37346791","id":"PMC_37346791","title":"Apoptosis-targeted gene therapy for non-small cell lung cancer using chitosan-poly-lactic-co-glycolic acid -based nano-delivery system and CASP8 and miRs 29A-B1 and 34A.","date":"2023","source":"Frontiers in bioengineering and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/37346791","citation_count":17,"is_preprint":false},{"pmid":"12097160","id":"PMC_12097160","title":"Monitoring of caspase-8/FLICE processing and activation upon Fas stimulation with novel antibodies directed against a cleavage site for caspase-8 and its substrate, FLICE-like inhibitory protein (FLIP).","date":"2002","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12097160","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53032,"output_tokens":4973,"usd":0.116846,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13031,"output_tokens":4722,"usd":0.091603,"stage2_stop_reason":"end_turn"},"total_usd":0.208449,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"CASP8 (MACH/FLICE) was cloned as a novel protein that binds MORT1/FADD via its prodomain and contains an ICE/CED-3-like protease domain. Cellular expression of proteolytic MACH isoforms causes cell death downstream of Fas/APO-1 and p55-TNF receptor, establishing CASP8 as the most upstream enzymatic component in death receptor-induced apoptosis cascades.\",\n      \"method\": \"Yeast two-hybrid cloning, co-immunoprecipitation, cellular overexpression assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — original cloning paper with reciprocal binding and functional overexpression data, independently replicated by concurrent studies (Srinivasula et al., PMID:8962078)\",\n      \"pmids\": [\"8681376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Recombinant Mch5/CASP8 (MACH/FLICE) is a mature two-subunit enzyme generated by autocleavage at Asp-227, Asp-233, Asp-391, and Asp-401. It directly processes and activates all known ICE/CED-3-like cysteine proteases (CPP32, Mch2, Mch3, Mch4, Mch6, ICE, TX, ICErelIII, ICH-1) and is potently inhibited by the cowpox serpin CrmA, placing it as the most upstream Fas-pathway protease.\",\n      \"method\": \"Bacterial recombinant expression, in vitro protease activity assays, N-terminal sequencing of cleavage products, CrmA inhibition assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted recombinant enzyme with in vitro substrate cleavage and inhibitor assays; replicated independently\",\n      \"pmids\": [\"8962078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CASP8/FLICE is activated at the CD95 (Fas/APO-1) DISC by a two-step proteolytic mechanism: initial cleavage generates p43 and p12 fragments; subsequent cleavage of receptor-bound p43 releases the active-site-containing p18 fragment and prodomain p26. Activation requires association with the DISC (mediated by N-terminal DED binding to FADD) and is blocked by zVAD-fmk, zDEVD-fmk, and zIETD-fmk but not by CrmA or Ac-YVAD-CHO.\",\n      \"method\": \"Biochemical fractionation, immunoprecipitation of DISC components, western blot with cleavage-site antibodies, peptide inhibitor studies, mass spectrometry identification of DISC proteins\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods defining cleavage mechanism in the DISC; independently corroborated by Boldin et al. and Srinivasula et al.\",\n      \"pmids\": [\"9184224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Recombinant FLICE/CASP8 directly activates downstream caspase zymogens in a cell-free system; CrmA attenuates this activation, consistent with CASP8 being the apical triggering protease in the CD95/TNFR-1-initiated caspase cascade.\",\n      \"method\": \"Cell-free system reconstitution, recombinant FLICE incubation with caspase zymogens, CrmA inhibition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with defined substrates and inhibitor; consistent with multiple independent studies\",\n      \"pmids\": [\"9006941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Among eight described CASP8 isoforms, only caspase-8/a and caspase-8/b are detectably expressed at the protein level in cells of diverse origin. Both isoforms are recruited to the CD95 DISC and activated upon CD95 stimulation with similar kinetics.\",\n      \"method\": \"Monoclonal antibody panel generation, western blotting, immunoprecipitation of DISC, kinetics of activation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antibody-based detection of specific isoforms at DISC, single lab, two orthogonal methods\",\n      \"pmids\": [\"9341131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Genetic complementation of a caspase-8-deficient Jurkat cell line demonstrates that CASP8 is essential and apical in the Fas-induced apoptotic cascade. Loss of CASP8 completely abrogates Fas-induced apoptosis and blocks activation of multiple downstream caspases as well as stress kinases p38 and JNK. The deficient line is also severely impaired in TNF-α-induced cell death.\",\n      \"method\": \"Genetic screen, isolation of caspase-8-deficient cell line, complementation with wild-type CASP8, caspase activity assays, kinase activation assays\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic loss-of-function with complementation rescue, multiple pathway readouts, defines epistatic position of CASP8\",\n      \"pmids\": [\"9740801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Anticancer drugs (daunorubicin, doxorubicin, etoposide, mitomycin C, cycloheximide) activate CASP8 in Jurkat cells independently of CD95 receptor/ligand interaction, as shown by equal drug-induced CASP8 activation in CD95-resistant cells and by failure of dominant-negative FADD (which blocks CD95 signaling) to prevent drug-induced CASP8 cleavage to its active p18 subunit.\",\n      \"method\": \"CD95-resistant cell lines, dominant-negative FADD overexpression, western blot for caspase-8 p18 fragment, caspase inhibitor studies\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (CD95-resistant cells, dominant-negative FADD, inhibitor studies) in one study; replicated by Engels et al. 2000\",\n      \"pmids\": [\"10216102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In the mitochondrial (drug-induced) apoptosis pathway, CASP8 acts as an amplifying executioner caspase downstream of the mitochondria, not as the initiating protease. Anticancer drugs still process caspase-9, -3, and Bid in CASP8-deficient Jurkat cells; Bcl-xL overexpression or dominant-negative caspase-9 blocks drug-induced CASP8 processing; in caspase-3-lacking MCF7 cells, CASP8 is not activated by drugs unless caspase-3 is restored by transfection.\",\n      \"method\": \"Caspase-8-deficient Jurkat cells, Bcl-xL overexpression, dominant-negative caspase-9, caspase-3-lacking MCF7 cells with caspase-3 transfection, western blotting\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic tools (KO cells, dominant-negative constructs, reconstitution) and orthogonal readouts; clearly distinguishes two CASP8 activation contexts\",\n      \"pmids\": [\"11030145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The CASP8 prodomain can be autocleavaged between its two tandem DEDs (at Asp129 by caspase-8 itself), generating a DEDa fragment. DEDa translocates to the nucleus via association with ERK1/2, interacts with TOPORS (a p53/topoisomerase I binding protein), and displaces p53 from TOPORS to allow p53-mediated stimulation of CASP8 gene expression, forming a positive feedback loop during apoptosis.\",\n      \"method\": \"In vitro cleavage assay, co-immunoprecipitation, nuclear fractionation, RNA interference of ERK1/2, reporter assays, confocal microscopy\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, nuclear fractionation, RNAi, and reporter assays in single lab; novel non-canonical mechanism\",\n      \"pmids\": [\"17290218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The C-terminal domain of c-FLIP(L) specifically inhibits the interaction of the CASP8 prodomain with the RIP1 death domain, thereby regulating CASP8-dependent NF-κB activation induced by FasL. The prodomain of CASP8 is sufficient to interact with RIP1 and to mediate NF-κB activation; c-FLIP(p43) (lacking the C-terminal domain) does not inhibit this interaction.\",\n      \"method\": \"Co-immunoprecipitation, mutant c-FLIP constructs (c-FLIPD376N, c-FLIPp43), HEK 293 cells lacking caspase-8, caspase inhibitor (zVAD), NF-κB reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IPs with domain mutants and genetic variants, single lab\",\n      \"pmids\": [\"24398693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CASP8 induces PD-L1 degradation by upregulating TNFAIP3 (A20), a ubiquitin-editing enzyme that promotes PD-L1 ubiquitination. Knockdown of CASP8 in melanoma cells increases PD-L1 levels and promotes tumor progression in an immune system-dependent manner.\",\n      \"method\": \"shRNA knockdown of CASP8 in mouse melanoma cells, in vivo tumor growth assays, western blot/ubiquitination assays for PD-L1, conditional NK-cell-specific CASP8 knockout mice (Ncr1iCre/+ Casp8fl/fl)\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo KD/KO approaches with mechanistic readouts, single lab\",\n      \"pmids\": [\"33934451\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TNF/IFNγ-induced CASP8 activation and cancer cell death require IRF1-mediated transcriptional upregulation of CASP8 (and CYLD). Additionally, ELAVL1 (HuR) binds CASP8 mRNA and stabilizes it under both basal and IFNγ-stimulated conditions; loss of ELAVL1 reduces CASP8 levels and blocks death receptor-initiated caspase-8-dependent apoptosis (from TNF, TRAIL, and FasL).\",\n      \"method\": \"Genetic screen, RNA immunoprecipitation (ELAVL1-CASP8 mRNA binding), IRF1 ChIP/transcription assays, mRNA stability assays, genetic KO of ELAVL1, caspase activity assays, cancer cell death assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic screen plus multiple mechanistic follow-up assays; single lab with orthogonal methods\",\n      \"pmids\": [\"38319288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FYCO1 (an autophagic vesicle transport protein) is a direct substrate of activated CASP8. CASP8 cleaves FYCO1 at aspartate 1306, releasing the C-terminal GOLD domain and inactivating FYCO1 function. Loss of FYCO1 sensitizes cells to TRAIL-induced apoptosis by stabilizing the DISC and impairing TNFRSF10B (TRAIL-R2/DR5) transport to lysosomes.\",\n      \"method\": \"Affinity purification/co-immunoprecipitation with activated CASP8, in vitro cleavage assay with mutagenesis of cleavage site (D1306), CRISPR/shRNA KO of FYCO1, DISC immunoprecipitation, receptor trafficking assays\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro cleavage with site-specific mutagenesis plus co-IP and functional genetic KO; multiple orthogonal methods in one study\",\n      \"pmids\": [\"37418591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Deletion of epithelial Casp8 in mice (Casp8∆IEC) results in ileocolitis, epithelial barrier dysfunction, reduced expression of Muc2 and defensins, and impaired body weight gain, establishing a required role for CASP8 in intestinal epithelial homeostasis. The intestinal phenotype is consistent with earlier work showing cFlip-regulated constitutive CASP8 activation.\",\n      \"method\": \"Conditional intestinal epithelial-specific CASP8 knockout mice, histology, endoscopy, gene expression analysis of barrier genes\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean conditional KO with defined phenotypic readouts; single lab, corroborates Wittkopf et al. 2013\",\n      \"pmids\": [\"31411503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"cFlip expression in intestinal epithelial cells is required for constitutive low-level activation of caspase-8 under steady-state conditions, which promotes cell survival. Conditional deletion of cFlip in adult intestinal epithelium leads to massive CASP8- and CASP3-dependent apoptosis and fatal intestinal destruction within days; cell death requires death receptor ligands (TNF-α, CD95L) and is independent of RIP3.\",\n      \"method\": \"Conditional (inducible and permanent) intestinal epithelial knockout of cFlip, caspase-8 and caspase-3 activity assays, histology, death receptor ligand neutralization experiments\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent conditional KO models (inducible and permanent), multiple mechanistic readouts, death receptor dependence confirmed\",\n      \"pmids\": [\"24036366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A 6-nucleotide deletion in the CASP8 promoter (-652 6N del) destroys an Sp1 binding site, decreases CASP8 transcription, and results in lower caspase-8 activity and reduced activation-induced T-cell death in response to cancer cell antigens.\",\n      \"method\": \"Promoter reporter assay, Sp1 binding site analysis, biochemical caspase-8 activity measurement in T lymphocytes from variant carriers, case-control genotyping\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assay plus functional caspase-8 activity in human lymphocytes; mechanistic follow-up supports the regulatory claim\",\n      \"pmids\": [\"17450141\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cleavage-site-directed antibodies demonstrate that CASP8/FLICE cleavage at the DISC and subsequent cleavage of its substrate FLIP (at LEVD376↓G) can be monitored in situ. Fas stimulation in IFN-γ-treated U937 cells markedly increases CASP8 processing; vitamin D3- or retinoic acid-differentiated Fas-resistant U937 cells show inhibited CASP8 processing, placing CASP8 activation upstream of changes in Fas sensitivity.\",\n      \"method\": \"Cleavage-site-directed antibodies, immunoblotting, flow cytometry, confocal microscopy, in vitro cleavage assays with GST-FLIP\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel cleavage-site antibodies validated in vitro and in cell-based assays; single lab, multiple detection methods\",\n      \"pmids\": [\"12097160\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CASP8 is an initiator cysteine protease recruited via its N-terminal death effector domains (DEDs) to the death-inducing signaling complex (DISC) formed at activated death receptors (Fas/CD95, TNFR1, TRAIL-Rs), where it undergoes two-step autoproteolytic activation to generate the active p18/p10 heterotetramer; active CASP8 then directly cleaves and activates downstream effector caspases (-3, -6, -7) and the BH3-only protein Bid to amplify apoptosis through the mitochondrial pathway, while in drug-induced (mitochondrial) apoptosis it acts instead as an amplifying executioner downstream of caspase-3; non-apoptotic functions include NF-κB activation via RIP1 interaction (regulated by c-FLIP(L) C-terminal domain), nuclear translocation of its autocleavage product DEDa to sustain CASP8 transcription, upregulation of A20 to promote PD-L1 ubiquitination and degradation, and cleavage of FYCO1 to inactivate vesicular transport of death receptors; its expression is regulated transcriptionally by IRF1 and post-transcriptionally by ELAVL1-mediated mRNA stabilization, and in the intestinal epithelium constitutive low-level CASP8 activation (controlled by cFLIP) is required for epithelial homeostasis and barrier integrity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CASP8 is an initiator cysteine protease that serves as the apical enzymatic trigger of death receptor-induced apoptosis, recruited through its N-terminal death effector domains to FADD/MORT1 at the death-inducing signaling complex (DISC) of Fas/CD95 and TNF receptors [#0, #2]. At the DISC, CASP8 is activated by a two-step autoproteolytic mechanism — an initial cleavage generating p43/p12 followed by release of the active-site p18 fragment — and this activation strictly requires DISC association and is blocked by IETD-type peptide inhibitors [#2]. Once active, recombinant CASP8 directly processes and activates the full set of downstream ICE/CED-3-family caspases (CASP3, CASP6, CASP7 and others) and is inhibited by the serpin CrmA, establishing it as the most upstream protease of the cascade [#1, #3]; genetic loss in Jurkat cells abolishes Fas-induced apoptosis and downstream caspase and stress-kinase activation, confirming its essential apical role [#5]. CASP8 function is context-dependent: in drug-induced (mitochondrial) apoptosis it is not the initiator but acts as an amplifying executioner downstream of mitochondria and caspase-3 [#6, #7]. Beyond apoptosis, CASP8 participates in non-death signaling — its prodomain interacts with RIP1 to drive NF-\\u03baB activation under control of the c-FLIP(L) C-terminal domain [#9], an autocleaved DEDa prodomain fragment translocates to the nucleus to sustain CASP8 transcription via TOPORS/p53 [#8], and active CASP8 cleaves the vesicular transport protein FYCO1 to modulate death receptor trafficking and TRAIL sensitivity [#12]. CASP8 levels are set transcriptionally by IRF1 and Sp1 and post-transcriptionally by ELAVL1-mediated mRNA stabilization [#11, #15]. In the intestinal epithelium, constitutive low-level CASP8 activation controlled by cFLIP is required for homeostasis and barrier integrity, and its loss causes ileocolitis and barrier dysfunction [#13, #14].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established the molecular identity of CASP8 and connected death receptor engagement to a proteolytic effector by showing it binds FADD via its prodomain and triggers cell death downstream of Fas and TNFR.\",\n      \"evidence\": \"Yeast two-hybrid cloning, co-immunoprecipitation, and overexpression-induced death assays\",\n      \"pmids\": [\"8681376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the activation mechanism or direct downstream substrates\", \"Overexpression-driven death may not reflect endogenous kinetics\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined CASP8 as a self-processing two-subunit enzyme and placed it atop the protease cascade by showing it directly cleaves all known ICE/CED-3 caspases in vitro and is blocked by CrmA.\",\n      \"evidence\": \"Bacterial recombinant enzyme, in vitro substrate cleavage, N-terminal sequencing, CrmA inhibition\",\n      \"pmids\": [\"8962078\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro substrate promiscuity may not reflect physiological selectivity\", \"Did not address how activation is gated in cells\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Resolved how CASP8 is activated in cells, showing a two-step DISC-localized cleavage requiring DED-mediated FADD binding, distinguishing receptor-proximal activation from cytosolic processing.\",\n      \"evidence\": \"DISC fractionation/immunoprecipitation, cleavage-site antibodies, peptide inhibitor and mass spectrometry studies\",\n      \"pmids\": [\"9184224\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of dimerization-induced activation not defined\", \"Did not quantify proximity-induced versus autocatalytic contributions\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Confirmed in a defined cell-free system that CASP8 directly initiates the downstream caspase cascade, consolidating its apical position.\",\n      \"evidence\": \"Cell-free reconstitution with recombinant FLICE and caspase zymogens plus CrmA inhibition\",\n      \"pmids\": [\"9006941\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish which caspases are direct physiological substrates in vivo\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Clarified which CASP8 isoforms operate physiologically, showing only caspase-8/a and /b are detectably expressed and are recruited to and activated at the DISC.\",\n      \"evidence\": \"Monoclonal antibody panel, western blotting, DISC immunoprecipitation, activation kinetics\",\n      \"pmids\": [\"9341131\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antibody detection from a single lab\", \"Function of remaining isoforms unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Provided genetic proof of essentiality, showing CASP8-deficient cells lose Fas apoptosis and downstream caspase/kinase activation, rescued by complementation.\",\n      \"evidence\": \"Caspase-8-deficient Jurkat line with wild-type complementation and pathway readouts\",\n      \"pmids\": [\"9740801\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not separate apoptotic from non-apoptotic CASP8 requirements\", \"Cell-line-specific epistasis\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Revealed a receptor-independent activation context, showing anticancer drugs activate CASP8 without CD95 ligand engagement or functional FADD.\",\n      \"evidence\": \"CD95-resistant cells, dominant-negative FADD, p18 western blotting, inhibitor studies\",\n      \"pmids\": [\"10216102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define whether CASP8 was initiator or amplifier in this context\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Reassigned CASP8's role in drug-induced apoptosis as an amplifying executioner downstream of mitochondria and caspase-3 rather than the initiator.\",\n      \"evidence\": \"CASP8-deficient Jurkat, Bcl-xL overexpression, dominant-negative caspase-9, caspase-3-null MCF7 reconstitution\",\n      \"pmids\": [\"11030145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger of CASP8 cleavage downstream of caspase-3 not detailed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Enabled in situ monitoring of CASP8 and FLIP cleavage and linked CASP8 processing to differentiation-dependent Fas sensitivity.\",\n      \"evidence\": \"Cleavage-site-directed antibodies, immunoblotting, flow cytometry, in vitro GST-FLIP cleavage\",\n      \"pmids\": [\"12097160\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab antibody reagents\", \"Mechanism linking differentiation to Fas resistance not fully defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Uncovered a non-apoptotic transcriptional feedback role, showing an autocleaved DEDa prodomain fragment enters the nucleus and sustains CASP8 expression via TOPORS/p53.\",\n      \"evidence\": \"In vitro cleavage, co-IP, nuclear fractionation, ERK1/2 RNAi, reporter assays, confocal microscopy\",\n      \"pmids\": [\"17290218\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab mechanism\", \"Physiological significance of the feedback loop in vivo unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established a functional promoter variant controlling CASP8 expression, showing a 6N deletion disrupting an Sp1 site lowers transcription, caspase-8 activity, and activation-induced T-cell death.\",\n      \"evidence\": \"Promoter reporter assays, Sp1 site analysis, caspase activity in carrier lymphocytes, case-control genotyping\",\n      \"pmids\": [\"17450141\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal disease link beyond association not established here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined a homeostatic survival role, showing cFLIP-controlled constitutive low-level CASP8 activation sustains intestinal epithelium and that cFLIP loss causes fatal CASP8/CASP3-dependent apoptosis requiring death receptor ligands.\",\n      \"evidence\": \"Inducible and permanent epithelial cFlip knockout mice, caspase activity assays, ligand neutralization\",\n      \"pmids\": [\"24036366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis distinguishing survival from death-inducing CASP8 activation unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated an intrinsic epithelial requirement for CASP8 in barrier integrity, with epithelial deletion causing ileocolitis and reduced Muc2/defensin expression.\",\n      \"evidence\": \"Intestinal epithelial-specific CASP8 knockout mice, histology, endoscopy, barrier gene expression\",\n      \"pmids\": [\"31411503\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking CASP8 loss to mucin/defensin reduction not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked CASP8 to anti-tumor immunity by showing it drives PD-L1 degradation via A20 (TNFAIP3) upregulation, with knockdown raising PD-L1 and promoting immune-dependent tumor growth.\",\n      \"evidence\": \"shRNA knockdown in melanoma, in vivo tumor assays, PD-L1 ubiquitination assays, NK-cell-specific conditional knockout\",\n      \"pmids\": [\"33934451\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether protease activity or scaffolding drives A20 upregulation unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified FYCO1 as a direct CASP8 substrate, showing cleavage at D1306 inactivates vesicular transport and modulates DISC stability and TRAIL receptor trafficking.\",\n      \"evidence\": \"Affinity purification, in vitro cleavage with D1306 mutagenesis, CRISPR/shRNA knockout, DISC IP, receptor trafficking assays\",\n      \"pmids\": [\"37418591\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of FYCO1 cleavage across cell types not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined dual regulation of CASP8 abundance, showing IRF1-driven transcription and ELAVL1-mediated mRNA stabilization are required for death receptor-initiated apoptosis.\",\n      \"evidence\": \"Genetic screen, RNA-IP, IRF1 ChIP, mRNA stability assays, ELAVL1 knockout, caspase/death assays\",\n      \"pmids\": [\"38319288\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interplay between transcriptional and post-transcriptional control not quantified\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the same enzyme switches between constitutive survival signaling, non-apoptotic NF-\\u03baB/transcriptional roles, and full apoptotic execution at the molecular level remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural/biochemical switch defined for survival versus death outputs\", \"In vivo substrate repertoire beyond caspases, Bid, FYCO1, and FLIP incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 2, 3, 12]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 2, 3]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 0]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 2, 5, 7]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 11]}\n    ],\n    \"complexes\": [\"DISC\"],\n    \"partners\": [\"FADD\", \"RIP1\", \"TOPORS\", \"FYCO1\", \"ELAVL1\", \"CFLAR\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}